Latest Nektar Therapeutics News & Updates

See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.

Nektar Therapeutics (Nektar)

Biopharmaceutical company developing autoimmune therapies

Latest news about Nektar Therapeutics (Nektar)

April 23 Nektar

Nektar Therapeutics closes $373.8 million public offering

The offering includes full exercise of underwriters' option for additional shares sold at $92.00 per share. Gross proceeds are approximately $373.8 million before expenses.
April 21 Nektar

Nektar Therapeutics prices upsized $325 million public offering

Sells 3,532,609 shares at $92 each. Proceeds fund R&D, clinical trials, manufacturing. Closes April 23, 2026.
April 20 Nektar

Nektar Therapeutics announces proposed $250M public offering

The offering includes common stock and pre-funded warrants, with an option for underwriters to buy additional shares. Proceeds will fund R&D, clinical trials, and manufacturing.
April 19 Nektar

Nektar announces conference call on REZOLVE-AA topline results

The call on April 20, 2026, reviews 52-week results from the 16-week extension of the Phase 2b trial of rezpegaldesleukin for alopecia areata.

Today Morningstar

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ...
Today Newser

NKTR (Nektar Therapeutics) posts narrower Q4 2025 loss than estimates, shares gain 1.67 percent in t...

Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections...
May 1 Morningstar

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options...
April 30 Morningstar

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain...

Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class...

Never miss news about Nektar

Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Nektar and other trending companies.